Anti-obesity compounds can influence differentiation, synthesis and lipolysis by modulating signaling pathways such as inflammation signaling pathways (NF-κb, MAPK, AP-1, etc.), glycometabolism signaling pathways (PGC-1α, ChREBP, GLUT1, etc.), adipocytokines (leptin, adiponectin), and so on. Here, SLC2A1 is linked to obesity disorder.